Plant Name: Castanea mollissima
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.517E-09 | 5.504E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.165E-09 | 6.734E-06 | FABP2, FABP3, FABP4, FABP5 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.529E-08 | 3.441E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.626E-08 | 3.962E-05 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.000E-07 | 2.722E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.322E-07 | 3.408E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 6.041E-07 | 3.484E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP5, LMNA, PPARA, PPARD, TLR2, TP53, TSHR |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.749E-06 | 8.280E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.924E-06 | 1.275E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.254E-06 | 1.684E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 5.363E-06 | 2.086E-03 | CYP1B1, FABP3, LMNA, PPARD, TLR2, TP53 |
| MF | GO:0005488; binding | GO:0097371; MDM2/MDM4 family protein binding | 1.022E-05 | 3.533E-03 | PPARA, TP53 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 1.363E-05 | 4.564E-03 | CYP1A1, CYP1A2 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 1.413E-05 | 4.661E-03 | FABP3, PPARA, PPARD |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 2.148E-05 | 6.879E-03 | PPARA, PPARD, TP53 |
| BP | GO:0008152; metabolic process | GO:1902894; negative regulation of pri-miRNA transcription from RNA polymerase II promoter | 2.673E-05 | 8.198E-03 | PPARA, PPARD |
| MF | GO:0005488; binding | GO:0036041; long-chain fatty acid binding | 2.673E-05 | 8.198E-03 | FABP3, PPARD |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 3.966E-12 | 2.856E-10 | FABP2; FABP3; FABP4; FABP5; PPARA; PPARD |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 6.236E-08 | 2.245E-06 | CYP1A2; CYP1A1; CYP1B1; CYP19A1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.657E-06 | 6.376E-05 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 5.249E-06 | 9.448E-05 | CYP1A1; CYP1B1; CYP19A1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.650E-05 | 2.376E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.340E-05 | 2.809E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 6.858E-04 | 7.054E-03 | FABP4; TSHR |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 9.229E-04 | 8.306E-03 | CYP1A2; CYP1A1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.190E-03 | 2.338E-02 | LMNA; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.790E-03 | 2.338E-02 | PPARA; TP53 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 3.959E-03 | 2.338E-02 | TP53; TLR2 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.547E-03 | 2.338E-02 | TP53; TLR2 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 4.307E-03 | 2.338E-02 | TP53; PPARD |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 8.609E-03 | 3.646E-02 | TP53; TLR2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 8.286E-03 | 3.646E-02 | PPARA; TSHR |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 7.198E-03 | 3.455E-02 | TP53; TLR2 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.495E-03 | 2.338E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PPARD |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | TP53; TLR2 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |